Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer

CDK4/6 inhibitors are effective against cancer cells expressing the tumor suppressor RB1, but not RB1-deficient cells, posing the challenge of how to target RB1 loss. In triple-negative breast cancer (TNBC), RB1 and PTEN are frequently inactivated together with TP53. We performed kinome/phosphatase...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jeff C., Granieri, Letizia, Shrestha, Mariusz, Wang, Dong-Yu, Vorobieva, Ioulia, Rubie, Elizabeth A., Jones, Rob, Ju, YoungJun, Pellecchia, Giovanna, Jiang, Zhe, Palmerini, Carlo A., Ben-David, Yaacov, Egan, Sean E., Woodgett, James R., Bader, Gary D., Datti, Alessandro, Zacksenhaus, Eldad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357459/
https://www.ncbi.nlm.nih.gov/pubmed/29617654
http://dx.doi.org/10.1016/j.celrep.2018.03.039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357459/
https://www.ncbi.nlm.nih.gov/pubmed/29617654
http://dx.doi.org/10.1016/j.celrep.2018.03.039

Ejemplares similares